Jeremy M Levin bought $50k of OVID
CEO at Ovid Therapeutics Inc.. 18,248 shares at an average of $2.76, traded Mar 18, 2024, filed Mar 20, 2024.
Score components
- +25RoleCEO
- +7Trade size$50k at market
- -5Relative to holdingsUnder 1% of holdings (0.5%)
- +8Price context32% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-24-005001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 18, 2024 | POpen-market purchase Common Stock | +18,248 | $2.76 | $50k | 3,616,715 | Mar 20, 2024 |
Related signals
Other insiders at Ovid Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Ovid Therapeutics Inc. | Margaret A. Alexander President and CEO | $17k 11,656 shares | -16% | |
| 23Weak | Ovid Therapeutics Inc. | Jeffrey A Rona CBFO | $12k 8,541 shares | -9% | |
| 20Weak | OVIDsell Ovid Therapeutics Inc. | Margaret A. Alexander President and COO | $2,956 5,279 shares | -7% | |
| 26Weak | OVIDbuy Ovid Therapeutics Inc. | Margaret A. Alexander President and COO | $4,971 6,810 shares | +24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.